Stone House Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Stone House Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$37.1K	Buy	83 +6	+8%	+$2.8K	0.01%	211
2025 Q4	$34.9K	Buy	77 +2	+3%	+$862	0.01%	201
2025 Q3	$29.4K	Buy	75 +1	+1%	+$418	﹤0.01%	194
2025 Q2	$32.9K	Sell	74 -25	-25%	-$11.5K	0.01%	182
2025 Q1	$48K	Buy	+99	New	+$46.1K	0.01%	150
2024 Q4	–	Sell	-124	Closed	-$57.7K	–	349
2024 Q3	$57.7K	Hold	124	–	–	0.01%	108
2024 Q2	$58.1K	Hold	124	–	–	0.02%	113
2024 Q1	$51.8K	Hold	124	–	–	0.01%	127
2023 Q4	$50.5K	Hold	124	–	–	0.02%	86
2023 Q3	$43.1K	Hold	124	–	–	0.02%	86
2023 Q2	$43.6K	Hold	124	–	–	0.02%	87
2023 Q1	$39.1K	Buy	+124	New	+$37.2K	0.01%	97

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Stone House Investment Management's VRTX Position: Q1 2026 in Review

Stone House Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 7.8% in Q1 2026, buying an estimated $2.8K and bringing the position to 83 shares worth $37.1K. The position accounts for 0.01% of the portfolio, ranked #211.

Stone House Investment Management first reported a position in VRTX in Q1 2023 and has held it in 12 quarters since. The position peaked at $58.1K in Q2 2024. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Stone House Investment Management held 83 shares of Vertex Pharmaceuticals worth $37.1K as of Q1 2026.
Stone House Investment Management bought 6 Vertex Pharmaceuticals shares in Q1 2026, an estimated $2.8K.
Vertex Pharmaceuticals made up 0.01% of Stone House Investment Management's portfolio in Q1 2026, its #211 holding.
Stone House Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
Stone House Investment Management's Vertex Pharmaceuticals position peaked at $58.1K in Q2 2024.
1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.